Literature DB >> 3291983

Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.

C A Hurwitz1, M R Loken, M L Graham, J E Karp, M J Borowitz, D J Pullen, C I Civin.   

Abstract

Cell surface phenotypes of 113 B lineage acute lymphocytic leukemia (ALL) cases, defined by the presence of HLA-DR and at least one B-cell-specific antigen (either CD19, CD20, or CD22), were compared with antigen-defined stages of normal B lymphocyte development. The cases were first evaluated for expression of HLA-DR, CD19, CD34, CD10, CD20, and CD22 by indirect one-color immunofluorescence. Pairwise comparisons of cell surface marker expression were performed for each leukemic sample: no correlations were observed for paired antigen expression on the leukemic samples using antigens expressed either early or late during normal B lymphoid development. Complete immunophenotypes of the cases were then compared with normal B-cell developmental stages. Sixteen different complete immunophenotypes were observed on the leukemias that were not found in normal marrow; at least 78% of the cases demonstrated such "asynchronous" combinations of B lymphoid-associated differentiation antigens. Several samples were subsequently studied by two-color immunofluorescence, and the presence of doubly labeled cells with "asynchronous" antigen combinations was confirmed. These results indicate that the majority of B lineage leukemias exhibit "developmental asynchrony," as compared with normal marrow B cells. The data further suggest that ALL cases do not accurately represent cells arrested at the stage where the leukemogenic event occurred. Rather, ALL appears to be a disease in which there may be maturation of leukemic blasts; but this maturation is "asynchronous" when compared with the normal developmental process.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3291983

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Detection of minimal residual disease in leukaemia.

Authors:  F E Katz
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

Review 2.  Early embryonal/fetal lymphopoietic ontogeny and leukemogenesis.

Authors:  G Prindull
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

3.  Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.

Authors:  C Stanciu-Herrera; C Morgan; L Herrera
Journal:  Leuk Res       Date:  2007-08-15       Impact factor: 3.156

4.  Routine immunophenotyping of acute leukemias.

Authors:  W D Ludwig; E Thiel
Journal:  Blut       Date:  1990-01

Review 5.  Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 6.  Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.

Authors:  Elaine Coustan-Smith; Dario Campana
Journal:  Best Pract Res Clin Haematol       Date:  2010-10-28       Impact factor: 3.020

7.  Expression of CD34 on human B cell precursors.

Authors:  C Schmitt; C J Eaves; P M Lansdorp
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

8.  Interleukin 4 inhibits in vitro proliferation of leukemic and normal human B cell precursors.

Authors:  D Pandrau; S Saeland; V Duvert; I Durand; A M Manel; M T Zabot; N Philippe; J Banchereau
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 9.  Minimal residual disease in acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 10.  Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.